BAM
AUTL

Bayshore Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Bayshore Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$18.4K – 36
2023
Q1 		$18.4K Hold
10,000
– – 0.01% 34
2022
Q4 		$19K Sell
10,000
-7,500
-43% -$19K 0.01% 31
2022
Q3 		$37K Hold
17,500
– – 0.03% 29
2022
Q2 		$50K Buy
+17,500
New +$53.3K 0.04% 30

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Bayshore Asset Management's AUTL Position: Q2 2023 in Review

Bayshore Asset Management sold out of Autolus Therapeutics (AUTL) in Q2 2023, closing a stake of 10,000 shares — an estimated $18.4K sold.

Bayshore Asset Management first reported a position in AUTL in Q2 2022 and held it in 4 quarters. The position peaked at $50K in Q2 2022. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2023.

  • Bayshore Asset Management reported no remaining Autolus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bayshore Asset Management sold 10,000 Autolus Therapeutics shares in Q2 2023, an estimated $18.4K.
  • Bayshore Asset Management first reported a position in Autolus Therapeutics in Q2 2022 and held it in 4 quarters.
  • Bayshore Asset Management's Autolus Therapeutics position peaked at $50K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2023.

Based on Bayshore Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.